Casdatifan (AB521)
Renal Cell Carcinoma
Phase 3Enrolling
Key Facts
About Arcus Biosciences
Founded in 2015, Arcus Biosciences is a clinical-stage biopharma with a mission to develop best-in-class cancer therapies through its proprietary 'Combining to Cure®' philosophy. The company has built a fully integrated platform, advancing a deep pipeline targeting key immuno-oncology pathways like adenosine signaling and TIGIT. With strategic partnerships, including a major collaboration with Gilead Sciences, and multiple programs in late-stage development, Arcus is positioned as a significant player in the next wave of oncology combination treatments.
View full company profileTherapeutic Areas
Other Renal Cell Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| LW-02 Immunopheresis | Immunicom | Phase 2 |
| CB-839 (Telaglenastat) | Calithera Biosciences | Phase 2 |
| XS008 (axitinib) | Xspray Pharma | Preclinical/Development |
| CDK7 allosteric inhibitor | Acellera | Pre-clinical |
| Precision Oncology - RCC | ReviveMed | Discovery |
| Lenvatinib (LENVIMA) | Eisai | Regulatory Review |
| Cabozantinib | Exelixis | Phase 3 |
| Zanzalintinib (XL092) | Exelixis | Phase 3 |
| XmAb®819 | Xencor | Phase 1 |